Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves’ Orbitopathy
Table 2
Range of parameters in the moderate-to-severe GO group with increased aminotransferases (values above the upper limit of normal are shown bold).
Moderate-to-severe GO group
Patient
Age
ALT (7–56 U/L)
AST (5–40 U/L)
TB (3.42–20.52 μmol/L)
A0
A1
A2
A3
A0
A1
A2
A3
A0
A1
A2
A3
1
42
79
34
20
18
35
20
7
10
16.07
6.84
6.67
6.67
2
38
68
56
51
37
28
22
25
18
4.10
5.47
8.38
6.50
3
43
26
40
28
33
21
14
9
14
26.00
35.57
39.33
31.98
4
55
20
21
21
17
19
18
16
19
22.06
17.10
18.81
20.52
5
73
18
16
18
14
22
17
16
14
31.63
23.94
29.41
31.81
6
45
18
17
19
25
22
20
12
20
26.33
7.35
13.51
17.44
7
54
28
28
29
42
31
25
29
41
4.45
8.72
6.33
14.54
8
46
53
51
57
23
25
23
16
20
12.65
10.77
12.48
7.18
9
44
12
39
72
14
13
17
20
8
13.85
9.58
15.73
12.83
10
24
12
16
15
37
17
13
11
21
18.81
17.10
25.31
19.67
ALT—alanine aminotransferase, AST—aspartate aminotransferase, TB—total bilirubin; A0—before treatment; A1—after administration of 0.5 g IVMP; A2—after administration of 3.0 g IVMP; A3—after administration of 4.5 g IVMP; GO—Graves’ orbitopathy.
